Drug Shortage Report for APIDRA

Last updated on 2023-07-12 History
Report ID 171433
Drug Identification Number 02279460
Brand name APIDRA
Common or Proper name Apidra Vials
Company Name SANOFI-AVENTIS CANADA INC
Market Status MARKETED
Active Ingredient(s) INSULIN GLULISINE
Strength(s) 100UNIT
Dosage form(s) SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS
Packaging size 1
ATC code A10AB
ATC description INSULINS AND ANALOGUES
Reason for shortage Other (Please describe in comments)
Anticipated start date
Actual start date 2022-10-06
Estimated end date 2023-07-31
Actual end date 2023-07-11
Shortage status Resolved
Updated date 2023-07-12
Company comments Supply delay. Shortage can be intermittent as Sanofi may receive partial shipments, until full resolution expected on “Estimated end date”. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date.
Health Canada comments
Tier 3 Status No
Company contact information email: CAINTERNET@sanofi.com Telephone: 1-800-265-7927

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v1 2022-10-07 English Compare
v2 2022-10-07 French Compare
v3 2022-10-07 English Compare
v4 2022-10-07 French Compare
v5 2022-10-07 English Compare
v6 2022-10-07 French Compare
v7 2022-10-31 English Compare
v8 2022-10-31 French Compare
v9 2022-10-31 English Compare
v10 2022-10-31 French Compare
v11 2022-11-10 English Compare
v12 2022-11-10 French Compare
v13 2023-07-11 English Compare
v14 2023-07-11 French Compare
v15 2023-07-12 English Compare

Showing 1 to 15 of 15